Some formulation aspects, facts & figures

Clinical nutrition products are described and characterised along their nutritional composition, caloric density and osmolality.

Figure 1: Formulation aspects in clinical nutrition

The nutritional composition of a clinical nutrition product is carefully designed. It contains protein, fat, carbohydrate, vitamins and minerals in such formulation that all relevant nutrients and the required energy are supplied in form of a complete and balanced diet. Next to standard formulations, the nutrient composition can be adjusted to nutritional and disease-specific requirements. A disease-specific formula for blood glucose control, for instance, contains primarily carbohydrates with low effect on blood glucose and insulin levels like isomaltulose. As a nutritive carbohydrate, isomaltulose adds to the caloric content of a product with 4 kcal/g. It contributes to the carbohydrate content of the formulation. In the nutrition information declaration it is considered under carbohydrates and, being a disaccharide, also under sugars.
The caloric density of clinical nutrition formulas varies between 1.0 and 2.0 kilocalories per millilitre product. With its 4 kilocalories per gram, isomaltulose contributes to the caloric value and thus to the caloric density of a formula to the same extent as other carbohydrates such as sugar, maltodextrins or starch.
The osmolality is also considered in clinical nutrition formulations. While general purpose formulas aim to have an osmolality similar to that of body fluids, nutrient-dense or hydrolysed formulas have a significantly higher osmolality. With a molar mass of 342.30 g·mol−1, isomaltulose adds to the osmolality of the product to the same extent as sucrose, and to less extent than monosaccharide sugars like glucose or fructose.

References

Alish CJ, Garvey WT, Maki KC, Sacks GS, Hustead DS, Hegazi RA, Mustad VA (2010) A diabetes-specific enteral formula improves glycemic variability in patients with type 2 diabetes. Diabetes Technol Ther 12 (6) 419-425. https://www.liebertpub.com/doi/10.1089/dia.2009.0185

Ang M, Linn T (2014) Comparison of the effects of slowly and rapidly absorbed carbohydrates on postprandial glucose metabolism in type 2 diabetes mellitus patients: a randomized trial. Am J Clin Nutr 100(4):1059–1068. https://ajcn.nutrition.org/content/early/2014/07/16/ajcn.113.076638.full.pdf+html

Bracken RM, Page R, Gray B, Kilduff LP, West DJ, Stephens JW, Bain SC (2012) Isomaltulose improves glycemia and maintains run performance in type 1 diabetes. Med Sci Sports Exerc 44(5):800–808. https://www.ncbi.nlm.nih.gov/pubmed/22051571

Kawai K, Yoshikawa H, Murayama Y, Okuda Y, Yamashita K (1989) Usefulness of palatinose as a caloric sweetener for diabetic patients. Horm Metab Res 21(6):338–340. https://www.ncbi.nlm.nih.gov/pubmed/2673967

Keyhani-Nejad F, Kemper M, Schueler R, Pivovarova O, Rudovich N, Pfeiffer AF (2016) Effects of Palatinose and Sucrose Intake on Glucose Metabolism and Incretin Secretion in Subjects With Type 2 Diabetes. Diab Care 39(3):e38-e39. https://www.ncbi.nlm.nih.gov/pubmed/26721819

König D, Theis S, Kozianowski G, Berg A (2012) Postprandial substrate use in overweight subjects with the metabolic syndrome after isomaltulose (Palatinose™) ingestion. Nutrition 28(6):651–656. https://www.ncbi.nlm.nih.gov/pubmed/22264450

Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: U.S. Department of Health and Human Services; 2014.

Oizumi T, Daimon M, Jimbu Y, Kameda W, Arawaka N, Yamaguchi H, Ohnuma H, Sasaki H, Kato T (2007) A palatinose-based balanced formula improves glucose tolerance, serum free fatty acid levels and body fat composition. Tohoku J Exp Med 212(2):91–99. https://www.ncbi.nlm.nih.gov/pubmed/17548953

Sakuma M, Arai H, Mizuno A, Fukaya M, Matsuura M, Sasaki H, Yamanaka-Okumura H, Yamamoto H, Taketani Y, Doi T, Takeda E (2009) Improvement of glucose metabolism in patients with impaired glucose tolerance or diabetes by long-term administration of a palatinose-based liquid formula as a part of breakfast. J Clin Biochem Nutr 45(2):155–162. https://www.ncbi.nlm.nih.gov/pubmed/19794923

van Can JG, van Loon LJ, Brouns F, Blaak EE (2012) Reduced glycaemic and insulinaemic responses following trehalose and isomaltulose ingestion: implications for postprandial substrate use in impaired glucose-tolerant subjects. Br J Nutr 108(7):1210–1217. https://www.ncbi.nlm.nih.gov/pubmed/22172468

Vanschoonbeek K, Lansink M, van Laere K, Senden JMG, Verdijk LB, van Loon LJ (2009) Slowly digestible carbohydrate sources can be used to attenuate the postprandial glycemic response to the ingestion of diabetes- specific enteral formulas. The Diabetes Educator 35, 631-640. https://journals.sagepub.com/doi/10.1177/0145721709335466

West DJ, Morton RD, Stephens JW, Bain SC, Kilduff LP, Luzio S, Still R, Bracken RM (2011) Isomaltulose improves postexercise glycemia by reducing CHO oxidation in T1DM. Med Sci Sports Exerc 43(2):204–210. https://journals.lww.com/acsm-msse/Fulltext/2011/02000/Isomaltulose_Improves_Postexercise_Glycemia_by.2.aspx